Table 1.
Individual Disclosures of the NCCN Non-Hodgkin’s Lymphomas Panel
| Panel Member | Clinical Research Support/Data Safety Monitoring Board | Scientific Advisory Boards, Consultant, or Expert Witness | Promotional Advisory Boards, Consultant, or Speakers Bureau | Date Completed |
|---|---|---|---|---|
| Jeremy S. Abramson, MD | Celgene Corporation; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Constellation, Inc.; Gilead Sciences, Inc.; Seattle Genetics, Inc.; and Pharmacyclics, Inc. | Amgen Inc.; Jannsen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; Gilead Sciences, Inc.; and Infinity Pharmaceuticals | Jannsen Pharmaceutica Products, LP; and Millennium Pharmaceuticals, Inc. | 10/9/14 |
| Ranjana H. Advani, MD | Celgene Corporation; Genentech, Inc.; Jannsen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; Agensys, Inc.; Allos Therapeutics; Idera Pharmaceuticals; Regeneron Pharmaceuticals, Inc.; Seattle Genetics, Inc.; and Pharmacyclics, Inc. | Genentech, Inc.; Clarient Diagnostic Services, Inc.; and Seattle Genetics, Inc. | None | 1/9/15 |
| C. Babis Andreadis, MD, MSCEa | GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; and AVEO Pharmaceuticals, Inc. | Bristol-Myers Squibb Company; Millennium Pharmaceuticals, Inc.; and Seattle Genetics, Inc. | None | 1/7/15 |
| Nancy Bartlett, MD | AstraZeneca Pharmaceuticals LP; Celgene Corporation; Genentech, Inc.; Jannsen Pharmaceutica Products, LP; MedImmune Inc.; Millennium Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Seattle Genetics, Inc.; Pfizer Inc.; and Pharmacyclics, Inc. | None | Gilead Sciences, Inc.; and Seattle Genetics, Inc. | 1/26/15 |
| John C. Byrd, MD | None | None | Genentech, Inc.; and Pharmacyclics, Inc. | 9/8/14 |
| Myron S. Czuczman, MD | Celgene Corporation; Onyx Pharmaceuticals, Inc.; and Gilead Sciences, Inc. | Boehringer Ingelheim GmbH; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Algeta; Gilead Sciences, Inc.; MorphoSys AG; Mundipharma International Ltd; TG Therapeutics, Inc.; and Teva Pharmaceutical Industries Ltd. | None | 5/22/14 |
| Luis E. Fayad, MD | Centocor, Inc.; Eisai Inc.; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Laboratories, Inc.; sanofi-aventis U.S.; and Wyeth Pharmaceuticals | None | None | 10/9/14 |
| Richard I. Fisher, MD | None | Celgene Corporation; Johnson & Johnson; and MorphoSys AG | None | 12/18/14 |
| Martha J. Glenn, MD | Amgen Inc.; Institutional DSMC; and sanofi-aventis U.S. | None | None | 12/15/14 |
| Leo I. Gordon, MD | Jannsen Pharmaceutica Products, LP | None | None | 12/16/14 |
| Thomas M. Habermann, MD | None | None | None | 10/31/14 |
| Nancy Lee Harris, MD | Pharmacyclics, Inc. | None | None | 1/26/15 |
| Richard T. Hoppe, MD | None | None | None | 12/15/14 |
| Steven M. Horwitz, MD | Celgene Corporation; Millennium Pharmaceuticals, Inc.; Infinity Pharmaceuticals; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; and Spectrum Pharmaceuticals, Inc. | Amgen Inc.; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Actelion Pharmaceuticals Ltd.; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; and Spectrum Pharmaceuticals, Inc. | Celgene Corporation | 1/6/15 |
| Christopher R. Kelsey, MD | Varian Medical Systems, Inc. | None | None | 1/30/15 |
| Youn H. Kim, MD | Eisai Inc.; Millennium Pharmaceuticals, Inc.; Kyowa Hakko Kirin Co., Ltd.; Seattle Genetics, Inc.; and Shape Pharmaceuticals, Inc. | Celgene Corporation; Eisai Inc.; Millennium Pharmaceuticals, Inc.; Actelion Pharmaceuticals Ltd.; Galderma S.A.; and OncoSec Medical Inc. | None | 12/15/14 |
| Susan Krivacic, MPAff | None | None | None | 12/29/14 |
| Ann S. LaCasce, MD | None | GlaxoSmithKline | None | 12/19/14 |
| Auayporn Nademanee, MD | Jannsen Pharmaceutica Products, LP; and Seattle Genetics, Inc. | Gilead Sciences, Inc. | None | 1/7/15 |
| Pierluigi Porcu, MD | Infinity Pharmaceuticals; OncoMed Pharmaceuticals, Inc.; and Seattle Genetics, Inc. | Celgene Corporation; Actelion Pharmaceuticals Ltd.; and Kyowa Hakko Kirin Co., Ltd. | Celgene Corporation; and Actelion Pharmaceuticals Ltd. | 9/19/14 |
| Oliver Press, MD, PhDb | Genentech, Inc.; and Roche Laboratories, Inc. | Adaptive Biotechnologies Corp. | None | 1/22/15 |
| Rachel Rabinovitch, MD | RTOG Data Safety and Monitoring Board | Accuray Incorporated | None | 1/26/15 |
| Nishitha Reddy, MD | Celgene Corporation | Jannsen Pharmaceutica Products, LP | None | 10/9/14 |
| Erin Reid, MD | Bristol-Myers Squibb Company; Jannsen Pharmaceutica Products, LP; Millennium Pharmaceuticals, Inc.; Abbvie Pharmaceuticals; AIDS Malignancy Consortium; CALGB/CTSU; Isis Pharmaceuticals, Inc.; Pharmacyclics, Inc.; and Takeda Pharmaceuticals North America, Inc. | None | None | 10/24/14 |
| Ayman A. Saad, MD | None | ICARE; and IMS Consulting Group | None | 12/18/14 |
| Lubomir Sokol, MD, PhD | None | Alexion Pharmaceuticals, Inc.; Celgene Corporation; and Spectrum Pharmaceuticals, Inc | Jannsen Pharmaceutica Products, LP; and Onyx Pharmaceuticals, Inc. | 12/15/14 |
| Lode J. Swinnen, MB, ChB | Abbott Laboratories | None | None | 10/10/14 |
| Christina Tsien, MD | None | None | None | 5/27/14 |
| Julie M. Vose, MD, MBA | Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Jannsen Pharmaceutica Products, LP; Onyx Pharmaceuticals, Inc.; Incyte Corporation; US Biotest, Inc.; Pharmacyclics, Inc.; and sanofi-aventis U.S. | None | None | 12/15/14 |
| William G. Wierda, MD, PhD | Abbott Laboratories; and GlaxoSmithKline | Celgene Corporation; Genentech, Inc.; and Roche Laboratories, Inc. | None | 10/8/14 |
| Lynn Wilson, MD, MPHa,b | None | None | None | 9/18/14 |
| Joachim Yahalom, MD | None | None | None | 8/18/14 |
| Nadeem Zafar, MD | None | None | None | 1/7/15 |
| Andrew D. Zelenetz, MD, PhD | Abbott Laboratories; Boehringer Ingelheim GmbH; Celgene Corporation; Genentech, Inc.; Jannsen Pharmaceutica Products, LP; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals, Inc.; Constellation Pharmaceuticals; Curis, Inc.; Gilead Sciences, Inc.; Infinity Pharmaceuticals; and Seattle Genetics, Inc. | Amgen Inc.; Celgene Corporation; Genentech, Inc.; Adaptive Biotechnologies Corp.; Alissa Pharma; Gilead Sciences, Inc.; Roche Laboratories, Inc.; and sanofi-aventis U.S. | None | 1/26/15 |
a
The following have disclosed a Spouse/Domestic Partner/Dependent Potential conflict: C. Babis Andreadis, MD, MSCE: Genentech, Inc. and Roche Laboratories, Inc. Lynn Wilson, MD: Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; ImmunoGen, Inc.; Isis Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; UCAN; UnitedHealthcare; and Vertex Pharmaceuticals Incorporated.
b
The following have disclosed an Employment/Governing Board, Patent, Equity, or Royalty conflict: Oliver Press, MD, PhD: Emergent Biosolutions Lynn Wilson, MD: Amgen Inc.; Biogen Idec; Bristol-Myers Squibb Company; Celgene Corporation; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; ImmunoGen, Inc.; Isis Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; UCAN; UnitedHealthcare; and Vertex Pharmaceuticals Incorporated. The NCCN Guidelines staff have disclosed that they have no conflicts of interest.